| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A302 | Genentech patent anti-Integrin β7 Featured |
|
|
| A303 | ADCT-901 Featured |
|
|
| A304 | ADCT-901-MMAE Featured |
|
|
| A305 | Macrogenics patent anti-KID3 Featured |
|
|
| A306 | Lirilumab Featured | Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. |
|
| A307 | Innate patent anti-KIR2DL Featured |
|
|
| A308 | Lacutamab Featured | Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma. |
|
| A309 | JNJ-69086420 Featured |
|
|
| A310 | Genentech patent anti-KLK5 Featured |
|
|
| A311 | NGM313 Featured |
|
|
| A312 | RG7992 Featured |
|
|
| A313 | Fianlimab Featured | Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. |
|
| A314 | Favezelimab Featured | Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab (HY-P9902). |
|
| A315 | Ieramilimab Featured | Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. |
|
| A316 | Encelimab Featured | Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft). |
|
| A317 | Relatlimab Featured | Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer. |
|
| A318 | Miptenalimab Featured | Miptenalimab (BI-754111) is an anti-human LAG-3 antibody (KD: 88.6 nM for h LAG-3). Miptenalimab blocks the interaction of LAG-3 with its ligand MHC-II. |
|
| A319 | SAR428926 Featured |
|
|
| A320 | Brigham and Womens anti-LAP Featured |
|
|
| A321 | Mibavademab Featured |
|
|
| A322 | MB-311 Featured |
|
|
| A323 | Anti-LIF Antibody (MSC-1) Featured |
|
|
| A324 | Polzastobart Featured | Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor. |
|
| A325 | Merck patent anti-ILT3 complex Featured |
|
|
| A326 | U.Texas patent anti-LILRB4 Featured |
|
|
| A327 | Opicinumab Featured | Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis. |
|
| A328 | Ladiratuzumab Featured | Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer. |
|
| A329 | Simtuzumab Featured | Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC). |
|
| A330 | RG7841 Featured |
|
|
| A331 | Anti-LY75/CD205 Antibody (MEN1309) Featured |
|
